BCD 263
Alternative Names: BCD-263Latest Information Update: 19 Oct 2024
At a glance
- Originator Biocad
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Malignant melanoma
Most Recent Events
- 21 Mar 2024 Phase-III clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Belarus (IV) (NCT06640530)
- 21 Mar 2024 Phase-III clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Pakistan (IV) (NCT06640530)
- 21 Mar 2024 Phase-III clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy) in Russia (IV) (NCT06640530)